Long-terms conditions (LTCs) affect more than 15 million people in England alone. As ICSs work in partnership to optimise pathways for those affected by LTCs while generating efficiency savings and capacity within already overstretched services, future service delivery will depend on understanding if earlier use of innovative medicines can be part of the solution.

This session will highlight the wider whole-system value of medicines with the speaker panel drawing on real examples of pathway redesign across the ICS network.

This session is supported by AbbVie.